Scarica l'app Stockscreener
6.74
4.01%
0.26
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.48
Aprire:
$6.55
Volume 24 ore:
938.02K
Relative Volume:
0.60
Capitalizzazione di mercato:
$319.22M
Reddito:
-
Utile/perdita netta:
$-54.19M
Rapporto P/E:
-2.6124
EPS:
-2.58
Flusso di cassa netto:
$-37.34M
1 W Prestazione:
+8.01%
1M Prestazione:
+17.12%
6M Prestazione:
+11.77%
1 anno Prestazione:
+57.48%
Intervallo 1D:
$6.52
$6.83
Intervallo di 1 settimana:
$6.145
$6.83
Portata 52W:
$3.9328
$7.3236
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Nome
Abeona Therapeutics Inc
Settore
Industria
Telefono
646-813-4701
Indirizzo
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Confronta ABEO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
6.74 | 319.22M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-03-05 | Iniziato | Oppenheimer | Outperform |
| 2024-07-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-30 | Iniziato | Stifel | Buy |
| 2020-11-11 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-02-10 | Iniziato | SVB Leerink | Outperform |
| 2019-12-10 | Ripresa | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Downgrade | Maxim Group | Buy → Hold |
| 2019-08-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Downgrade | Mizuho | Buy → Neutral |
| 2019-06-27 | Iniziato | Mizuho | Buy |
| 2018-10-12 | Iniziato | Mizuho | Buy |
| 2018-06-05 | Iniziato | Seaport Global Securities | Buy |
| 2017-11-08 | Iniziato | SunTrust | Buy |
| 2017-10-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-11 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Iniziato | Citigroup | Buy |
| 2017-10-05 | Reiterato | Maxim Group | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-07-18 | Reiterato | Maxim Group | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-01-06 | Iniziato | Jefferies | Buy |
| 2016-09-29 | Reiterato | Maxim Group | Buy |
Mostra tutto
Abeona Therapeutics Inc Borsa (ABEO) Ultime notizie
ABEONA THERAPEUTICS Executives Sell Shares to Cover Tax Obligations - TradingView
Abeona Therapeutics Officer Sells Shares to Cover Tax Obligations - TradingView
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade) - Seeking Alpha
Abeona Therapeutics at Jefferies Conference: ZivaSkin’s Promising Launch By Investing.com - Investing.com Canada
Abeona Therapeutics (ABEO) Gains "Outperform" Rating from Oppenheimer | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Gains Oppenheimer's Outperform Rating with Promising Outlook | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Gains Oppenheimer's Outperform Rating - GuruFocus
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees - GuruFocus
Abeona Therapeutics Announces New Employee Inducement Grants - marketscreener.com
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees | ABEO Stock News - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Un - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona Therapeutics Awards Stock Grants Worth 11,500 Shares: New Employee Compensation Details Revealed - Stock Titan
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Abeona Therapeutics® to Present at the Jefferies Global Healthca - GuruFocus
Abeona Therapeutics Inc. CEO and CCO to Speak at Jefferies Global Healthcare Conference on June 4, 2025 - Nasdaq
Abeona Therapeutics Leadership to Share Latest Company Updates at Major Healthcare Conference - Stock Titan
Trading (ABEO) With Integrated Risk Controls - news.stocktradersdaily.com
Director Cashes In on Abeona Therapeutics Stock! - TipRanks
Insider Sell: Mark Alvino Sells Shares of Abeona Therapeutics In - GuruFocus
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionAbeona Therapeutics (NASDAQ:ABEO), Ascentage Pharma Group (NASDAQ:AAPG) - Benzinga
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket - Benzinga
ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight - PR Newswire
Dystrophic Epidermolysis Bullosa Market Predicted to See - openPR.com
ABEO: Sells Priority Review Voucher for $155 Million… - MSN
Abeona Therapeutics finally expanding to make cell-based gene therapy - The Business Journals
Abeona Therapeutics Elects New Directors at Meeting - TipRanks
ABEO: Sells Priority Review Voucher for 155 Million - Smartkarma
Abeona targets treating 10–14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runway - MSN
Stifel Nicolaus Issues Pessimistic Forecast for Abeona Therapeutics (NASDAQ:ABEO) Stock Price - Defense World
(ABEO) Trading Report - news.stocktradersdaily.com
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q1 2025 Earnings Call Transcript - Insider Monkey
Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Lowered by StockNews.com - Defense World
Stifel cuts Abeona Therapeutics price target to $20, maintains Buy By Investing.com - Investing.com South Africa
Abeona Therapeutics Reports Improved Financial Performance - TipRanks
Insider Selling: Mark Alvino Sells Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus
Abeona Therapeutics (ABEO) Transitions to Commercial Stage with ZEVASKYN Launch - GuruFocus
Abeona Therapeutics’ Earnings Call Highlights ZEVASKYN Success - TipRanks
Stifel cuts Abeona Therapeutics price target to $20, maintains Buy - Investing.com Australia
Abeona Therapeutics (ABEO): Stifel Lowers Price Target | ABEO St - GuruFocus
Abeona Therapeutics (ABEO): Stifel Lowers Price Target | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Receives Revised Price Target Amid Po - GuruFocus
Abeona Therapeutics: Q1 Earnings Snapshot - CT Insider
Earnings call transcript: Abeona Therapeutics beats EPS forecast in Q1 2025 - Investing.com Nigeria
Abeona Therapeutics (ABEO) Target Price Raised Following FDA Approval and Strategic Sale | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Exceeds EPS Estimates, Bolstered by S - GuruFocus
ABEO Shows Decrease in Cash Reserves Before PRV Sale Completion - GuruFocus
Abeona Therapeutics (ABEO) Launches ZEVASKYN, A Milestone in Gen - GuruFocus
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates | ABEO Stock News - GuruFocus
Abeona Therapeutics Inc Azioni (ABEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Abeona Therapeutics Inc Azioni (ABEO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Seshadri Vishwas | Chief Executive Officer |
Jun 06 '25 |
Sale |
6.76 |
50,676 |
342,570 |
1,303,761 |
| O'Malley Brendan M. | SVP, General Counsel |
Jun 06 '25 |
Sale |
6.76 |
10,470 |
70,777 |
378,245 |
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):